47
Participants
Start Date
June 12, 2015
Primary Completion Date
September 29, 2016
Study Completion Date
September 29, 2016
vortioxetine
Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
Massachusetts General Hospital, Boston
Takeda Pharmaceuticals North America, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER